Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response With Imatinib

Next Previous
Search
Trial Profile

Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Philadelphia-Positive Chronic Myeloid Leukemia, Who Had Previously Achieved a Deep Molecular Response With Imatinib

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms PONAZERO

    • Most Recent Events

    • 12 Dec 2023 Results (n=23)presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 15 Jun 2023 Interim results of PONAZERO (NCT04043676) & RESTOP (NCT04160546) assessing use of ponatinib 15mg daily for 12 months, presented at the 28th Congress of the European Haematology Association.
    • 22 Feb 2023 Results (n=9) evaluating the persistence of TKI-mediated protective activity against HIV in CD4 from individuals who received one-year treatment with ponatinib against chronic myeloid leukemia, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top